Fig. 1 · Structure
Documents & Downloads
MRE-269-d7
IP Receptor Agonist
MRE-269-d7 is a deuterium-labeled derivative of MRE-269, which serves as an active metabolite of selexipag. This compound functions as a selective agonist of the IP receptor, playing a critical role in research related to pulmonary arterial hypertension and vascular biology. Its unique properties make it suitable for studies investigating the modulation of prostacyclin pathways and their physiological effects.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 1265295-20-2 |
| Applications | IP Receptor Agonist |
| Formula | C25H22D7N3O3 |
| Molecular Weight | 426.56 |
| Synonyms | ACT-333679-d7 |
| SMILES | OC(COCCCCN(C([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])C1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)N=C1)=O |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.